Hydrochloric Acid

Hydrochloric Acid

SCHEMBL2138964

CCCCCCCCCC(N)(CCCCCCCC)CCCCCCCC.Cl

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
S1PR1 known ✓ P21453 1/20 0.42
SMPD1 P17405 4/20 0.48
FDPS P14324 2/20 0.48
DNM1 Q05193 8/20 0.48
TSHR P16473 2/20 0.47
THRB P10828 1/20 0.47
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
ALDH1A1 P00352 1/20 0.43
EPHX1 P07099 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL108550 1.00 SMPD1 (0.48) SMPD1FDPSDNM1TSHRTHRB
Hydrochloric Acid SCHEMBL5084753 1.00 SMPD1 (0.48) SMPD1FDPSDNM1TSHRTHRB
Hydrochloric Acid SCHEMBL1665720 1.00 SMPD1 (0.48) SMPD1FDPSDNM1TSHRTHRB
Hydrochloric Acid SCHEMBL9775488 1.00 SMPD1 (0.48) SMPD1FDPSDNM1TSHRTHRB
Hydrochloric Acid SCHEMBL10694855 1.00 SMPD1 (0.48) SMPD1FDPSDNM1TSHRTHRB
Hydrochloric Acid SCHEMBL10695022 1.00 SMPD1 (0.48) SMPD1FDPSDNM1TSHRTHRB
Hydrochloric Acid SCHEMBL6376295 1.00 SMPD1 (0.48) SMPD1FDPSDNM1TSHRTHRB
Hydrochloric Acid SCHEMBL8824219 1.00 SMPD1 (0.48) SMPD1FDPSDNM1TSHRTHRB
Hydrochloric Acid SCHEMBL6262112 1.00 SMPD1 (0.48) SMPD1FDPSDNM1TSHRTHRB
Hydrochloric Acid SCHEMBL9722909 1.00 SMPD1 (0.48) SMPD1FDPSDNM1TSHRTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6936187-B2 Functionalized cubic liquid crystalline phase materials and methods for their preparation and use CHILDREN'S HOSPITAL RESEARCH FOUNDATION 2005-08-30 US claimed
WO-2025121285-A1 PHOSPHINE-PALLADIUM COMPLEX, POLYMERIZATION CATALYST, AND METHOD FOR PRODUCING AROMATIC POLYMER 日本化学工業株式会社 2025-06-12 WO disclosed
WO-2025070024-A1 ORGANOSILICON COMPOUND, RUBBER COMPOSITION, AND RUBBER MATERIAL 株式会社大阪ソーダ 2025-04-03 WO disclosed
CN-113454090-B Compounds having a polycyclic aromatic skeleton and endoperoxide compounds thereof 川崎化成工业株式会社 2024-08-23 CN disclosed
US-12065521-B2 Compound having polycyclic aromatic skeleton, and endoperoxide compound of same KAWASAKI KASEI CHEMICALS LTD. (JP) 2024-08-20 US disclosed
US-11958802-B2 Migration-resistant photopolymerization sensitizer KAWASAKI KASEI CHEMICALS LTD. (JP) 2024-04-16 US disclosed
CN-113166036-B Photopolymerizing sensitizers with migration resistance 川崎化成工业株式会社 2023-10-10 CN disclosed
EP-3760613-B1 METHOD FOR PRODUCING MERCAPTOPHENOL COMPOUND AND INTERMEDIATE OF SAID COMPOUND KUMIAI CHEMICAL INDUSTRY CO (JP) 2023-01-25 EP disclosed
US-11420928-B2 Polymer photopolymerization sensitizer KAWASAKI KASEI CHEMICALS LTD. (JP) 2022-08-23 US disclosed
CN-110691765-B High molecular photopolymerization sensitizer 川崎化成工业株式会社 2022-05-17 CN disclosed
WO-2002068562-A2 FUNCTIONALIZED CUBIC LIQUID CRYSTALLINE PHASE MATERIALS AND METHODS FOR THEIR PREPARATION AND USE THE PROCTER & GAMBLE COMPANY (US) 2002-09-06 WO disclosed
US-20020082348-A1 Process for producing an epoxidized polymer KURARAY CO. LTD, (JP) 2002-06-27 US disclosed
EP-1217011-A1 Process for producing an expoxidized polymer KURARAY CO., LTD. (JP) 2002-06-26 EP disclosed
US-6300446-B1 Fluorine-containing copolymer and composition thereof ASAHI GLASS COMPANY, LIMITED (JP) 2001-10-09 US disclosed
EP-1090935-A1 FLUOROCOPOLYMER AND COMPOSITION THEREOF ASAHI GLASS COMPANY LTD. (JP) 2001-04-11 EP disclosed
US-5344902-A Addition type without solvent, casting OCCIDENTAL RESEARCH CORPORATION (US) 1994-09-06 US disclosed
EP-0268261-A1 Process for producing 1-hydrocarbyl mercaptans PHILLIPS PETROLEUM COMPANY (US) 1988-05-25 EP disclosed
EP-0095096-B1 IMPROVED METHOD OF SYNTHESIS OF 1-SUBSTITUTED AZACYCLOALKAN-2-ONES Whitby Research Incorporated (US) 1987-11-04 EP disclosed
US-4422970-A ALKYLATION OF AZACYCLOHEPTAN-2-ONE, QUATERNARY AMMONIUM PHASE TRANSFER CATALYST NELSON RESEARCH & DEVELOPMENT COMPANY (US) 1983-12-27 US disclosed
US-3960762-A Production of absorbents BAYER AKTIENGESELLSCHAFT (DT) 1976-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11420928-B2 Polymer photopolymerization sensitizer PCNA, RAD51, H1-10 S1PR1 2679/4885SMPD1 4407/4885FDPS 2774/4885
US-11958802-B2 Migration-resistant photopolymerization sensitizer F12, F10, PCNA S1PR1 1646/4885SMPD1 2809/4885FDPS 1627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.